Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
110 results about "Proto-Oncogenes" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Normal cellular genes homologous to viral oncogenes. The products of proto-oncogenes are important regulators of biological processes and appear to be involved in the events that serve to maintain the ordered procession through the cell cycle. Proto-oncogenes have names of the form c-onc.
Method for treating cancer using p38/JTV-1 and method for screening pharmaceutical composition for treating cancer
The present invention relates to a method for treating cancer using p38 / JTV-1 and a method for screening pharmaceutical composition for treating cancer. More particularly, this invention relates to the method for treating cancer, which comprises administering the effective amount of p38 / JTV-1 protein or a nucleic acid encoding for said protein to the patient and the method for screening a pharmaceutical composition for treating cancer characterized by selecting a substance having an effect on the increase of the activity of the p38 / JTV-1 protein and the intracellular level thereof.The method according to the invention can be effectively used to treat cancer through the mechanism of suppressing the proliferation of cancer cells by binding to FBP (FUSE-binding protein) and thereby promoting the ubiquitination of FBP to downregulate c-myc gene, which is a proto-oncogene, and the mechanism of promoting the apoptosis of cells by binding to PDK-1 (phosphoinositide-dependent protein) and thereby inhibiting the phosphorylation of AKT (serine / threonine kinase). Also, p38 / JTV-1 can be used as a target for screening of new anticancer agents, by virtue of such regulation mechanisms of p38 / JTV-1.
Owner:MEDICINAL BIOCONVERGENCE RES CENT
Use of protein biomolecular targets in the treatment and visualization of brain tumors
Owner:ER SQUIBB & SONS INC
Delivery of therapeutic agent
ActiveUS20160168572A1Improve target specificityImprove targetingNervous disorderSpecial deliveryCancer cellGene product
A method of producing nanovesicles comprising an oligonucleotide inhibitor to an oncogene or a proto-oncogene or the gene product thereof, said method comprises a) introducing a DNA sequence encoding an oligonucleotide capable of inhibiting a human oncogenic or proto-oncogenic transcription factor, into a mammalian cell; b) allowing the cell to express said inhibitor oligonucleotide; and c) obtaining nanovesicles containing said inhibitor oligonucleotide from said cell. Nanovesicles produced by the claimed method can be effectively and specifically targeted to e.g. cancer cells to deliver the inhibitor oligonucleotide.
Owner:CODIAK BIOSCI
Bisfatty amido substituted quinazolone derivatives as well as preparation method and use thereof as anti-cancer drugs
InactiveCN101250189AGood antitumor activitySmall toxicityOrganic active ingredientsOrganic chemistryQuinoxalineTelomerase
The invention discloses a dual fatty ammonia substituted quinazolinone derivative, represented as formula (I), wherein n is 1, 2, 3, 4 or 5, R1 and R2 are same or different, selected from the alkyl of H and C1-6, and naphthenic group, piperidyl, morpholinyl, piperazinyl or quinoxaline of C3-6. The derivative has strong interaction on the telomere DNA rich with guanine and c-myc DNA of proto-oncogene, strong inhibition on telomere / telomerase of cancer cell and strong inhibition on the c-myc expression of proto-oncogene. The derivative has low toxicity and side effect, which can be developed to a new anti-tumor drug. The derivative has simple preparation method, cheap materials and strong inhibition on various cancer cell lines, which can be prepared into anti-tumor drug, with wide application.
Owner:SUN YAT SEN UNIV
Ruthenium (II) polypyridine complex and preparation method and application thereof
InactiveCN105732723AThe synthesis steps are simpleHigh yieldOrganic active ingredientsRuthenium organic compoundsTelomerasePhenanthroline
The invention relates to ruthenium (II) polypyridine complex.The complex uses 2-(1, 10-phenanthroline monohydrate-5-base)-benzimidazole) as the main ligand and 2, 2'-bipyridine or 1, 10'-phenanthroline as the auxiliary ligand, and the chemical formula of the complex is [Ru(bpy)2pbi]2+ or [Ru(phen)2pbi]2+.A preparation method of the complex includes the steps of firstly, preparing pbi; secondly, synthesizing a ruthenium metal compound with the auxiliary ligand group; thirdly, synthesizing the target ruthenium (II) polypyridine complex; fourthly, using silica gel chromatography column separation to obtain the product.The ruthenium (II) polypyridine complex is used for preparing medicine combining with telomere G-quadruplex to increase the stability of the telomere G-quadruplex.Compared with the prior art, the ruthenium (II) polypyridine complex prepared by the method has the advantages that the ruthenium (II) polypyridine complex can recognize, combine and stabilize the telomere G-quadruplex, inhibit telomerase activity and regulate proto-oncogene expression, and a theoretical foundation is provided for anticancer medicine screening.
Owner:TONGJI UNIV
Quinnazolidone derivative, preparation method thereof and purpose of serving as anticarcinogen
InactiveCN101857595AStrong inhibitory activityGood anticancer effectOrganic chemistryAntineoplastic agentsQuinoxalineCancer cell
The invention belongs to the medicine and chemical industry field, which discloses a quinnazolidone derivative, a preparation method thereof and a purpose of serving as anticarcinogen. The structural formula of the quinnazolidone derivative is that: R1 is F, CL, Br or I, R2 is NH (CH2) nNR4, NR4 or NH(CH2)n-Ar, R3 is NHCO (CH2) nNR4 or CONH (CH2) nNR4, and m equals to 1,2 or 3. -Ar represents various aromatic nucleus, including various heteroaromatic compounds; n equals to 1, 2, 3, 4 or 5; R4 represents C1-6alkyl, C3-6 naphthenic base, piperidyl, morpholinyl, piperazine, or quinoxaline and the like or R1 equals to H, R2 equals to R3 equals to NHCO (CH2) nNR4 or R2 equals to H, R1 equals to R3 equals to NHCO (CH2) nNR4, and m equals to 2 or 3. The invention discloses the preparation method of the quinnazolidone derivative and the purpose of serving as the anticarcinogen at the same time. The quinnazolidone derivative has the advantages of strong inhibitory action on the expression of telomere DNA, c-myc and other proto-oncogenes DNA, obvious inhibitory action on various cancer cell strains, little toxicity on normal cells and wide application space on preparing the anticarcinogen.
Owner:SUN YAT SEN UNIV
Method and device for detecting gene fusion mutation, storage medium, processor and method for normalizing transcription group data expression quantity
ActiveCN109637587AQuick comparisonQuick checkoutMicrobiological testing/measurementProteomicsMutation typeSignificant difference
The invention discloses a method and device for detecting gene fusion mutation, a storage medium, a processor and a method for standardizing the transcription group data expression quantity so as to reduce the false positivity of detection. The method comprises the following steps of: detecting whether a sample to be detected accords with a known fusion mutation type from a transcript level; if not, detecting whether the sample to be detected has potential fusion, wherein the potential fusion comprises at least one of the following: unknown fusion exists on the transcript level of a protooncogene; the protooncogene has structural fusion at the genome level; if so, detecting whether the potential fusion is sense fusion or not, and if so, detecting whether the expression level of the protooncogene is abnormal in the following two aspects: over-expression of a functional area of the protooncogene; significant differences in the expression quantities of the protooncogene in 5'and 3'ends. If yes, judging to be positive, otherwise judging to be negative. The method integrates multi-dimensional fusion characteristics to reduce false positives of detection results.
Owner:ZHENYUE BIOTECHNOLOGY JIANGSU CO LTD
Methods for Cancer Diagnosis, Anti-Cancer Drug Screening, and Test of Drug Effectiveness on the Basis of Phoshorylation of Ras at Thr-144 and Thr-148
InactiveUS20110189693A1Improve effectivenessMicrobiological testing/measurementImmunoglobulins against animals/humansMedicineCancers diagnosis
Methods of diagnosing cancer and screening for an anti-cancer drug using Ras are provided. Ras has a very significant role as a prevalent proto-oncogene which has abnormalities in most forms of cancer, and thus the methods of diagnosing cancer and screening for an anti-cancer drug using Ras may be applied to various forms of cancer. The generation of various forms of cancer in the early stages may be determined by examining whether or not phosphorylation of Ras occurs at Thr-144 and Thr-148 sites, By such a mechanism, an anti-cancer drug having excellent anti-cancer effectiveness may be screened, or the effectiveness of the anti-cancer drug may be tested.
Owner:IND ACADEMIC CORP FOUND YONSEI UNIV
Peptide derivative of benzfuran quinoline and preparation method thereof and application thereof as antitumor medicament
InactiveCN102516355AStrong interactionStrong inhibitory activityDipeptide ingredientsTetrapeptide ingredientsChemical industryCancer cell
The invention belongs to the fields of medicaments and chemical industry, and discloses a peptide derivative of benzfuran quinoline and a preparation method thereof and an application thereof as an antitumor medicament. The structural formula of the peptide derivative of benzfuran quinoline is shown in the specifications, wherein R is a peptide chain, i.e., R, GG, GR, GK, GH, GF, HR, KR, FR, GGR, GFR, GFRK, GFHR or GGGR; R represents arginine; G represents glycine; K represents lysine; H represents histidine; and F represents phenyl alanine. The invention further discloses a preparation method of the peptide derivative of benzfuran quinoline and an application of the peptide derivative as an anticancer medicament. As proved by an experiment, the peptide derivative of benzfuran quinoline related to the invention has a very strong inhibiting effect on the expression of telomere DNAs (Deoxyribose Nucleic Acids) and proto-oncogene DNAs such as c-myc and the like, a remarkable inhibiting effect on various cancer cell lines, low toxicity on normal cells and a wide application space on the preparation of an anticancer medicament.
Owner:SUN YAT SEN UNIV
Methylbenzofuran quinoline derivative, preparation method thereof, and application of derivative as antitumor drug
ActiveCN103382207AStrong interactionStrong inhibitory activityOrganic active ingredientsOrganic chemistryCancer cellMethyl palmoxirate
The invention discloses a methylbenzofuran quinoline derivative, a preparation method thereof and application of the derivative as an antitumor drug, which belongs to the fields of medicine and chemical engineering. The invention also discloses the preparation method for the methylbenzofuran quinoline derivative and application of the derivative as the antitumor drug. According to results of experiments, the methylbenzofuran quinoline derivative in the invention has a powerful inhibitory effect on the expression of protooncogenes of DNA like telomeric DNA and c-myc, a substantial inhibitory effect on a variety of cancer cell lines, small toxicity to normal cells and wide application prospects in preparation of antitumor drugs.
Owner:SUN YAT SEN UNIV
Medicinal composition containing realgar
ActiveCN102119958ALow toxicityImprove anti-tumor effectOrganic active ingredientsInorganic active ingredientsOxymatrineGINSENG EXTRACT
The invention provides a medicinal composition containing realgar. Particularly, the medicinal composition contains realgar microbiological leaching liquid, a ginseng extract, an astragalus extract and oxymatrine. An animal experiment shows that the medicinal composition has an obvious down-regulation effect on excessive activation of a path of a proto-oncogene Ras and low toxicity; therefore, the medicinal composition is suitable to be applied in the preparation of an antineoplastic medicine.
Owner:李红玉
Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby
InactiveUS20050123896A1Easy to addImprove stabilitySugar derivativesMicrobiological testing/measurementAbnormal tissue growthMammal
This invention pertains to the development of a screening system to identify (screen for) HER2 promoter silencing agents. Such agents are expected to be of therapeutic value in the treatment of cancers characterized by HER2 amplification / upregulation. In addition, this invention pertains to the discovery that histone deacetylase (HDAC) inhibitors like sodium butyrate and trichostatin A (TSA), in a time and dose dependent fashion can silence gnomical.ly integrated and / or amplified / overexpressing promoters, such as that driving the HER2 / ErbB2 / neu oncogene, resulting in inhibition of gene products including transcripts and protein, and subsequent production of tumor / cell growth inhibition, apoptosis and / or differentiation. In another embodiment, this invention provides novel SNPs associated with the coding region of the ErbB2. proto-oncogene. The SNPs are indicators for altered risk, for developing ErbB2-positive cancer in a mammal
Owner:THE BUCK INST FOR RES ON AGING
Application of inhibitor of GINS2 genes or protein to preparation of antitumor drugs
ActiveCN106620703APrevent proliferationGrowth inhibitionOrganic active ingredientsMicrobiological testing/measurementLentivirusApoptosis
The invention relates to application of an inhibitor of GINS2 genes or protein to the preparation of antitumor drugs. A small-molecular interference RNA sequence aiming at the human GINS2 genes, an RNA interference vector and an RNA interference lentivirus are designed, the silencing efficiency of the GINS2 genes and influence of the GINS2-siRNA lentivirus on the proliferation capacity and apoptosis level of tumor cells are further detected, results show that the proliferation and growth of the tumor cells can be inhibited effectively and the apoptosis of the tumor cells can be promoted after an RNAi method is used to lower the expression of the GINS2 genes, the results indicate that the GINS2 genes are proto-oncogenes and can be used as the targets of tumor treatment, and the RNAi method for silencing the expression of the GINS2 can be used as an effective method to inhibit tumor development. The built siRNA, the RNA interference vector and the RNA interference lentivirus can be used for preparing efficient antitumor drugs.
Owner:SHANGHAI SEVENTH PEOPLES HOSPITAL
Novel human cell growth inhibiting gene THAP11 and application thereof
InactiveCN101712959APeptide/protein ingredientsMicrobiological testing/measurementAbnormal tissue growthWilms' tumor
The invention provides a novel human cell growth inhibiting gene and an application of an encoded protein. The gene and the encoded protein are related to the regulation and control of a cell cycle, can inhibit the growth of tumor cells by inhibiting the expression of a proto oncogene c-Myc, and are down-regulated in various tumor tissues, thereby having a close relation with the generation of tumors. The gene and the encoded protein and derivatives thereof can be used for the diagnosis, treatment and drug screening for tumors caused by disordered regulation and control of cell cycles and neurodegenerative diseases and the like.
Owner:INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA
Oncogenes and methods for their detection
InactiveUS6713619B1Immune responseSimple diagnostic assaySugar derivativesPeptide/protein ingredientsCancer cellNucleic Acid Probes
Experiments designed to define the differences between the 21 oncogene of DNA isolated from human bladder cancer cells and its corresponding proto-oncogene are described herein. Also described is the determination of the difference between the rat neu oncogene and its corresponding proto-oncogene. Also described are nucleic acid probes reactive with regions of the proto-oncogene or oncogene, as are methods for their use in detecting the occurrence of the two types of genes. Antibodies specific for gene products encoded by the neu genes are also described, as are methods for their use.
Owner:MASSACHUSETTS INST OF TECH
Compound for selectively degrading CDK subtype in targeted manner and application thereof
InactiveCN110938060APrevent proliferationOrganic active ingredientsOrganic chemistryMetaboliteCancer cell
The invention discloses a compound for selectively degrading a CDK subtype in a targeted manner, and belongs to the field of biomedicine. The compound is a compound shown as a formula I or a stereoisomer, a geometrical isomer, a tautomer, a nitrogen oxide compound, a hydrate, a solvent compound, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and can selectively degrade CDK2or CDK2 / 9 so as to block the synthesis process of DNA and achieve the proliferation of cancer cells, wherein certain compounds capable of selectively degrading CDK subtypes in the targeted manner canalso down-regulate signal channels including proto-oncogene products c-MYC and MCL-1, can strongly inhibit the proliferation of cancer cells, and have a potential treatment effect. X-Y-Z Formula I isperformed, wherein: X represents a cyclin kinase inhibitor, Z represents a CRBN ligand, Y represents a chain linking X and Z, and X is a structure as shown in a formula II or a formula III.
Owner:SICHUAN UNIV
Use of phosphorylation pathway-related factor in regulating function of regulatory t cell
InactiveUS20150073043A1Enhancing vaccine immunogenicityImproving immunogenicityCompound screeningBiocideDiseasePIM1
A method for the treatment and / or the prevention of a disease or a symptom related to dysfunction of regulatory T cell immunomodulation includes administering to a subject in need thereof compositions that regulate regulatory T cell immunomodulatory function, in which the compositions may be prepared by contacting starting materials with phosphorylation pathway-related factors, the agonists or the antagonists thereof. The phosphorylation pathway-related factors are selected from: proto-oncogene protein PIM1 and the coding sequence thereof. The regulation is achieved by regulating the activity of regulators of regulatory T cells selected from the group: FOXP3, IL-2, GITR, CTLA4, and a combination thereof.
Owner:INST PASTEUR OF SHANGHAI CHINESE ACADEMY OF SCI
Multiplex RT-PCR (reverse transcription-polymerase chain reaction) reagent kit for detecting leukemia BCR-ABL (Abelson proto-oncogene-breakpoint cluster region)
InactiveCN103627810AAvoid it happening againAvoid pollutionMicrobiological testing/measurementMyeloid leukemiaReverse transcriptase
The invention discloses a multiplex RT-PCR (reverse transcription-polymerase chain reaction) reagent kit for detecting leukemia BCR-ABL (Abelson proto-oncogene-breakpoint cluster region) and relates to leukemia detection. With the adoption of a technology of multiplex RT-PCR in combination with capillary electrophoresis, three fusion forms, namely e1a2, e13a2 and e14a2, of the BCR-ABL can be detected simultaneously by a single PCR, and the detection time and cost are effectively saved. The length of an amplification product can be judged quickly, efficiently and accurately according to a chromatogram by taking the three fusion forms, namely e1a2, e13a2 and e14a2, constructed by an overlap extension method as positive quality controls. The kit is applicable to multiple fields of qualitative detection and diagnosis, selection of auxiliary clinical medication and prognosis judgment of the different fusion forms, namely e1a2, e13a2 and e14a2, of BCR-ABL fusion genes in acute lymphoblastic leukemia patients and a few acute myeloid leukemia patients.
Owner:XIAMEN UNIV
Use of protein biomolecular targets in the treatment and visualization of brain tumors
The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents which specifically bind to one or more of human proteins angiopoietin related protein 2 (ARP-2,) secreted protein acidic, rich in cysteine (SPARC,) c-met proto-oncogene (C-MET,) brevican (BEHAB,) CD-44 antigen (CD-44,) tetraspanin 3 (TSPN3,) pleiotrophin (PTN,) osteopontin (OPN,) vasoactive intestinal peptide receptor-2 (VIPR-2,) and receptor protein tyrosine phosphatase zeta (PTPζ) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. The present invention also provides novel splice variants of protein PTPζ, PTPζ SM1 and PTPζ SM2. Nucleic acid probes specific for the spliced mRNA encoding these variants and affinity reagents specific for the novel proteins are also provided.
Owner:MEDAREX LLC
Detection method of human proto-oncogene KRAS and kit
InactiveCN101736080AHigh degree of standardizationImproving the Meaning of Results AnalysisMicrobiological testing/measurementExonWilms' tumor
The invention provides a detection method of KRAS gene mutation and a kit. The detection method comprises the following steps of: (a) extracting DNA in the sample, and carrying out PCR amplification by using specific primers under specified conditions; and (b) and sequencing the amplified products, comparing with normal KRAS gene, and determining whether gene mutation exists. The specific primers are 2-4 pairs of primers aiming at different exons of the KRAS gene. By adopting the detection method and the kit of the invention, the detection speed can be improved and the reagent and time are saved. By utilizing the detection result, the administration for clinical chemotherapy of alimentary tract tumors can be guided.
Owner:GENESKY BIOTECH INC
Genetic therapy breast cancer drug preparation method based on microfluidic chip
InactiveCN101745121AMicrobiological testing/measurementGenetic material ingredientsTherapeutic effectC erbb 2
The invention discloses a genetic therapy breast cancer drug preparation method based on microfluidic chip, which includes that: the method adopts biological molecules as computation medium to compute the cancer-related gene expression through biochemical reaction; when the result meets the requirement, the anti-cancer drug is automatically synthesized and released in targeted manner; the anti-cancer drug is complete suicide gene; the biological molecules used as computation medium are DNA molecules and / or enzyme; the oncogene related to breast cancer includes: C-erbB-2, EGFR, c-myc, ras, int-2, bcl-2, BAG-1, BCSG-2 and survivin; the cancer suppressor gene related to breast cancer includes P53, nm23, PTEN, Rb, P16, P21, CHEK2, BRCA1 and BRCA2. The invention can synthesize and release anti-cancer drugs for breast cancer on specified conditions; and the anti-cancer drugs are complete suicide gene. The method can be combined with the nanometer technology and micromachining technology to help improve the treatment effect.
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
Peptidyl-substituted double-chain benzofuran quinoline derivative as well as preparation method and application thereof
ActiveCN104017047AStrong inhibitory activityPreparation is not limitedDipeptide ingredientsTetrapeptide ingredientsDipeptideCancer cell
The invention provides a peptidyl-substituted double-chain benzofuran quinoline derivative. The structural formula of the peptidyl-substituted double-chain benzofuran quinoline derivative is shown in formula (I). In the formula (I), R1 is dipeptide, tripeptide, tetrapeptide and pentapeptide. Experiments prove that the peptidyl-substituted double-chain benzofuran quinoline derivative provided by the invention has very strong inhibition effects on expression of proto-oncogene DNA (deoxyribonucleic acid) such as telomere DNA, c-myc and the like, has significant inhibition effects on various cancer cell lines, has low toxicity to normal cells, is a peptide chain substituted benzofuran quinoline compound with low toxicity and good anti-cancer effects, and has wide application spaces in preparation of anti-cancer medicaments.
Owner:SUN YAT SEN UNIV
Mutant met and uses therefor
The present invention provides compositions and methods for detecting mutations in the proto-oncogene Met.
Owner:RGT UNIV OF CALIFORNIA
Gene joint detection method and kit
ActiveCN104480215AStrong specificityNo non-specific interfering signalsMicrobiological testing/measurementDNA/RNA fragmentationViral OncogeneMultiplex ligation-dependent probe amplification
The invention relates to a joint detection method for gene mutation. The joint detection method is characterized in that 16 gene mutations, including KRAS (Kirsten rat sarcoma viral oncogene homolog), PIK3CA (phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit alpha), BRAF (B-Raf proto-oncogene, serine / threonine kinase) and EGFR (Epidermal Growth Factor Receptor) genes can be detected synchronously by using 20-50ng of DNA as a sample. The method comprises the steps of designing a specific probe; building a reaction system for an MLPA (Multiplex Ligation Dependent Probe Amplification) mutant gene sequences; largely amplifying the targeted gene sequences by PCR (Polymerase Chain Reaction). The joint detection method for gene mutation has the advantages that the specificity is high, and 10-100ng of wild type DNA do not generate nonspecific interference signals; the selectivity is outstanding, and 0.1 to 1.0% of mutation can be detected under the background of 99-99.9% of wild type DNA.
Owner:南宁维尔凯生物科技有限公司
Application of RET proto oncogene 634 polymorphism sites in drug preparation
InactiveCN103409513AImprove diagnosis rateTimely treatmentMicrobiological testing/measurementGenes mutationMultiple endocrine neoplasms
The invention belongs to the field of medicine biology, and relates to an application of RET proto oncogene 634 polymorphism sites in preparation of drugs for screening and diagnosis of multiple endocrine neoplasm type 2A. According to the research, DNA is extracted from MEN2A proband peripheral blood karyote, RET proto oncogene hot spot mutation sites are subjected to PCR amplification, direct sequencing is performed, and detection results are that: the pathogenic gene RET gene mutation site of MEN2A is mainly 634 site, the highest proportion of p.C634R (rs75076352) is 42.22%, and the proportion of p.C634Y (rs75996173) is 26.67%, such that the two polymorphism active sites such as the rs75076352 and the rs75996173 are applied in preparation of drugs for screening and diagnosis of multiple endocrine neoplasm type 2A so as to increase multiple endocrine neoplasm type 2A diagnosis rate, and timely treat patients.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Delivery of therapeutic agent
ActiveUS9856477B2Increase concentrationEasy loadingNervous disorderSpecial deliveryCancer cellGene product
Owner:LONZA SALES AG
Medication selection and curative effect detection reagent kit of glivec assistance treatment of gastrointestinal stromal tumor
The invention discloses a medication selection and curative effect detection reagent kit of glivec assistance treatment of a gastrointestinal stromal tumor, and relates to a detection reagent kit for molecular biology and medicine. The kit comprises BCR-ABL (Abelson proto-oncogene-breakpoint cluster region) gene PCR (polymerase chain reaction) liquid, Taq (thermus aquaticus) enzyme, a control, a matched multiplex PCR amplification procedure and a wrappage. The kit helps to select appropriate drugs for the gastrointestinal stromal tumor and evaluates a curative effect of the individual glivec assistance treatment of the gastrointestinal stromal tumor by detecting whether a glivec drug target site BCR-ALB fusion gene exists, and is applicable to multiple fields of selection of clinical assistance medication, prognosis judgment and the like of the gastrointestinal stromal tumor.
Owner:XIAMEN UNIV
Recombination adenovirus for curing overexpression proto-oncogene neu/erbB2 malignancy
InactiveCN101054596AGenetic material ingredientsMammal material medical ingredientsProto-Oncogene NeuBinding site
The present invention relates to a method for constructing a recombinant adenovirus for expressing neu / erbB2 proto-oncogene human-source antibody variable region and Mda-7 / IL-24 expression box structure, and its uses. The expression box is characterized as 1) neu / erbB2 proto-oncogene human-source antibody variable region, 2) Mda-7 / IL-24 being 206 amino acid gene fragment, the 72 position amino acid converting from Ala to Val, 3) connecting neu / erbB2 proto-oncogene human-source antibody variable region and Mda-7 gene through inner ribosome binding site(IRES), 4) the adenovirus being duplication-defective serum A5 type adenovirus. The novel adenovirus expresses two kinds of anti-cancer gene, that is neu / erbB2 proto-oncogene human-source antibody variable region and Mda-7 gene, whose product has strong cell apotosis function and does no harm to normal cell so it has significance in gene therapy for malignant tumour of over expression for neu / erbB2 proto-oncogene.
Owner:王尚武
Construction method and application of primary MM (multiple myeloma) mouse model
PendingCN108424933ANormal immune systemMolding fastFermentationVector-based foreign material introductionTreatment targetsBiology
The invention discloses a construction method and an application of a primary MM (multiple myeloma) mouse model. The method comprises steps as follows: high-frequency mutated proto-oncogenes are screened from sequencing results of MM patient samples and taken as driver genes, and a retroviral vector is constructed, infects IgM positive B cells of a mouse in vitro and performs induced transformation into an MM model in the body of the mouse; proto-oncogene combinations of ten patients are screened out, and cMYC and KRAS12V are determined to be the best. The model is applied to research of humanMM pathogenesis, chemical drug screening of MM, improvement of existing therapeutic schedules, evaluation of new drug or targeted drug combination and evaluation of the model for cellular immunotherapy and antibody therapy. The constructed primary MM model has great significance for scientific research of molecular mechanism of MM genesis and development and exploration of new MM treatment targets. The animal module is fast to form and realizes 100% tumor formation, and a theoretical basis and an evaluation system are provided for development of new target identification and new treatment method evaluation of MM on the basis of biotherapy.
Owner:贵州康钦承平生物科技有限公司
Carbazole derivative, preparation method thereof, and application of carbazole derivative serving as anticancer drug
InactiveCN102491972AStrong inhibitory activityStrong interactionOrganic active ingredientsOrganic chemistryChemical industryCancer cell
The invention belongs to the fields of medicament and chemical industry, and discloses a carbazole derivative, a preparation method of the carbazole derivative, and an application of the carbazole derivative serving as an anticancer drug. The structural formula of the carbazole derivative is shown in the specification, wherein R1 is piperidyl, morpholinyl, piperazinyl or Bielin group; n is 1, 2 or 3; and R2 is pyrazolyl or pyridyl. At the same time, the invention discloses a preparation method of the carbazole derivative and an application of the carbazole derivative serving as the anticancer drug. The carbazole derivative has strong inhibiting action on the expression of telomere DNA (deoxyribonucleic acid) and DNA of c-myc and other proto-oncogene, has significant inhibiting action on multiple cancer cell strains, has low toxicity to normal cells, and has broad application space in preparation of anticancer drugs.
Owner:SUN YAT SEN UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com